NovaBay Pharmaceuticals Strengthens Global Aganocide(R) Patent Estate With Seven New Patents
May 31, 2012 18:07 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 31, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage biotechnology company developing first-in-class "non-antibiotic anti-infective"...
NovaBay Enrolls First Patients in Global BAYnovation(TM) Phase 2b Study for Adenoviral Conjunctivitis
May 17, 2012 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Study Design Includes FDA Recommendations Following Successful End-of-Phase 2a Meeting
EMERYVILLE, Calif., May 17, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY),...
NovaBay Pharmaceuticals Provides Q1 - 2012 Financial Results
May 03, 2012 08:05 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing novel anti-infective products for the treatment and...
NovaBay's Aganocide Out-Performed Traditional Antibiotics in Drug Resistance Study
May 02, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Findings Published in Antimicrobial Agents and Chemotherapy Show Resistance to NVC-422 Does Not Emerge in S. aureus Including MRSA, P. aeruginosa, and E. coli Bacteria
EMERYVILLE, Calif., May 2,...
NovaBay's NeutroPhase(R) Supports Healing of Chronic Wounds
April 19, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
New Patient Case Studies Highlighted at the 2012 Spring Symposium on Advanced Wound Care
EMERYVILLE, Calif., April 19, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY),...
NovaBay to Present New Case Studies on NeutroPhase(R) at the 2012 Spring Symposium on Advanced Wound Care
April 16, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 16, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY), a biotech company developing novel anti-infective products for the treatment and prevention...
NovaBay Pharmaceuticals Launches CEO Blog
April 05, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Follow NovaBay on Twitter, Facebook and Linkedin
EMERYVILLE, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company...
NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2011 Financial Results
March 27, 2012 07:45 ET
|
NovaBay Pharmaceuticals, Inc.
Progress Continues in Company's Four Business Units:
Ophthalmology: Enrollment in global adenoviral conjunctivitis study to begin Q2-2012.
Urology: Demonstrated 80% effectiveness...
NovaBay Pharmaceuticals Signs Option Agreement With Virbac Animal Health for Aganocide(R) Compounds
March 20, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company today announced that it has entered into a feasibility...
NovaBay Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
March 06, 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...